.jpg?format=webp&width=780)
Left atrial appendage closure (LAAC) is an alternative to long-term oral anticoagulation for preventing embolic events in individuals with nonvalvular atrial fibrillation. However, LAAC is associated with the risk of device-related thrombosis, necessitating the use of antithrombotic treatment. The ideal antithrombotic regimen for LAAC, which effectively prevents device-related thrombus formation while minimizing bleeding risk, is still uncertain. Over the course of more than 10 years of experience with LAAC, various antithrombotic treatments have been employed, primarily in observational studies. This review examines the existing evidence for each antithrombotic regimen following LAAC, offering guidance for physicians and highlighting future prospects in the field.
Like
Save
Share